申请人:Kimura Tomio
公开号:US20090306059A1
公开(公告)日:2009-12-10
A compound having the general formula (I), pharmacologically acceptable salts thereof or prodrugs thereof:
[wherein R
1
represents a hydrogen atom, a C1-C6 alkyl group which may be substituted, a C3-C6 cycloalkyl group which may be substituted, a C1-C6 alkoxy group which may be substituted or a C6-C10 aryl group which may be substituted;
R
2
represents a hydrogen atom, a halogen atom, a carboxy group, a C2-C7 alkoxycarbonyl group, a carbamoyl group, a cyano group, a C1-C6 alkyl group, a halogeno C1-C6 alkyl group, a C1-C6 alkyl group substituted by a heteroaryl group, a C1-C6 alkoxy group, a halogeno C1-C6 alkoxy group, a hydroxy C1-C6 alkyl group, a C2-C12 alkoxyalkyl group, a formyl group, a C2-C7 alkanoyl group, a C4-C7 cycloalkylcarbonyl group, a C2-C7 alkylcarbamoyl group, a di(C1-C6 alkyl)carbamoyl group, a group of formula R
4
—CO—CR
5
R
6
—(CH
2
)
m
—, a group of formula R
7
—CO—(CH
2
)
l
—N(R
8
)— or a sulfamoyl C1-C6 alkyl group;
R
3
represents a substituted C1-C6 alkyl group, a heterocyclyl group or a heterocyclyl group substituted with 1 to 5 substituents;
X
1
, X
2
, X
3
, X
4
and X
5
each independently represents a hydrogen atom, a halogen atom, an amino group, a carboxy group, a carbamoyl group, a cyano group, a nitro group, a C1-C6 alkyl group, a halogeno C1-C6 alkyl group, a C1-C6 alkoxy group, or a halogeno C1-C6 alkoxy group; and
n represents an integer of 0 to 2].
具有通式(I)的化合物,其药学上可接受的盐或前药:
[其中R1代表氢原子,可能被取代的C1-C6烷基,可能被取代的C3-C6环烷基,可能被取代的C1-C6烷氧基或可能被取代的C6-C10芳基;
R2代表氢原子,卤原子,羧基,C2-C7烷氧羰基,氨基甲酰基,氰基,C1-C6烷基,卤代C1-C6烷基,被杂环芳基取代的C1-C6烷基,C1-C6烷氧基,卤代C1-C6烷氧基,羟基C1-C6烷基,C2-C12烷氧基烷基,甲酰基,C2-C7烷酰基,C4-C7环烷基羰基,C2-C7烷基氨基甲酰基,二(C1-C6烷基)氨基甲酰基,通式R4—CO—CR5R6—(CH2)m—的基团,通式R7—CO—(CH2)l—N(R8)—或磺胺基C1-C6烷基;
R3代表取代的C1-C6烷基,杂环烷基或带有1至5个取代基的取代的杂环烷基;
X1、X2、X3、X4和X5分别独立地代表氢原子,卤原子,氨基,羧基,氨基甲酰基,氰基,硝基,C1-C6烷基,卤代C1-C6烷基,C1-C6烷氧基或卤代C1-C6烷氧基;以及
n代表0至2的整数。